New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
06:54 EDTTSROTESARO data adds marketing strength, says Mizuho
Mizuho believes the data presented over the weekend by TESARO adds to the U.S. marketing story of rolapitant. The firm says it is incrementally more positive on the stock and keeps a Buy rating on TESARO with a $44 price target.
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 12, 2015
08:24 EDTTSROTESARO expands niraparib clinical program, provides update on FY15 milestones
TESARO provided an update on its late-stage programs. New trial of niraparib for the treatment of ovarian cancer to begin in Q1. HRD assay to be incorporated into Phase 3 NOVA trial of niraparib in ovarian cancer. Initial Phase 3 data from NOVA is expected to become available in 2015. FDA PDUFA action date for oral rolapitant is September 4, 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use